Line 1: |
Line 1: |
− | Text
| + | {| class="wikitable" |
| + | |'''Alteration''' |
| + | |'''Relevant Gene(s)''' |
| + | |'''CGC Evidence Level''' |
| + | |'''Subgroup Association(s)''' |
| + | |- |
| + | |1q gain |
| + | | unknown |
| + | |2 |
| + | |Most common copy number alteration, often with 16q loss; all subtypes |
| + | |- |
| + | |8p11.2 amplification |
| + | |''FGFR1'', ''ZNF703'' |
| + | |2 |
| + | |METABRIC IntClust6, ER positive |
| + | |- |
| + | |8q24 amplification |
| + | |''MYC'' |
| + | |2 |
| + | |METABRIC IntClust9, ER positive |
| + | |- |
| + | |9p24 amplification |
| + | |''JAK2, CD274, PDCD1LG2'' |
| + | |2 |
| + | |Enriched in TNBC |
| + | |- |
| + | |10q23.3 loss or LOH |
| + | |''PTEN'' |
| + | |2 |
| + | |Enriched in TNBC and in lobular carcinoma |
| + | |- |
| + | |11q13-q14 gain / amplification |
| + | |''CCND1'', ''EMS1'', and others |
| + | |2 |
| + | |METABRIC IntClust2 |
| + | |- |
| + | |16q loss / LOH |
| + | |''CDH1'' |
| + | |2 |
| + | |METABRIC IntClust2, ER positive |
| + | |- |
| + | |17p loss / LOH |
| + | |''TP53'' |
| + | |2 |
| + | |TNBC, basal-like intrinsic subtype |
| + | |- |
| + | |17q12 amplification |
| + | |''ERBB2'' (''HER2'') |
| + | |1 |
| + | |METABRIC IntClust5, HER2-enriched |
| + | |- |
| + | |17q21 amplification |
| + | |''TOP2A'' |
| + | |2 |
| + | |METABRIC IntClust5, HER2-enriched |
| + | |- |
| + | |17q23 amplification (“17q distal amplicon”) |
| + | |''RPS6KB'', others |
| + | |2 |
| + | |METABRIC IntClust1 |
| + | |- |
| + | |19q12 |
| + | |''CCNE1'' |
| + | |2 |
| + | |METABRIC IntClust5; HER2-enriched |
| + | |- |
| + | |20q gain; 20q13 amp |
| + | |''AURKA'', ''GNAS'', ''ZNF217'' |
| + | |2 |
| + | |METABRIC IntClust1, ER Positive |
| + | |} |